Login
Contact

Explore

Explore

About
  • People and Partners
  • TRI Building
  • Reconciliation Action Plan
  • Strategic Plan
  • TRI Foundation
  • Careers
Research
  • Collaborate
  • Discovery
  • Translate
  • Engage
  • Research Areas
Clinical
  • Translational Trials
  • Clinical Research Facility
  • TRI at Children’s
Industry
  • TRI Incubator
  • The Precinct
  • Residents
Manufacture
  • New cGMP Facility
Facilities
  • Cleanroom
  • Flow Cytometry
  • Histology
  • Microscopy
  • Proteomics
  • Preclinical Imaging
  • Biological Research
  • Gnotobiotics
  • Human Immune Model
Get Involved
  • Health Consumers
  • SPARQ-ed
Resources
  • News
  • Events
  • Case Studies
  • Grants and Funding
  • Education and Training

+61 7 3443 7000info@tri.edu.au37 Kent Street, Woolloongabba QLD 4102 Australia

Acknowledgement of Country

TRI acknowledges the traditional custodians of the land we are on today, the Turrbal and Jagera people and we recognise their continuing connection to land, waters and community. We pay deep respect to them and their cultures; and to Elders past, present and emerging.

© Translational Research Institute Pty Ltd atf the Translational Research Institute Trust|ABN: 58 155 991 662
Privacy policy|Terms of Use|Contact Us
TRI · Get Involved · Case Studies

Case Studies

Get InvolvedNewsEventsCase StudiesGrants and FundingEducation and TrainingSPARQ-ed
Phase I Clinical Trial

New Human Immune Models set to accelerate preclinical drug development

TRI-based Professor Kristen Radford from Mater Research is leading development of new preclinical research models that are core to TRI’s new Human Immune Model Facility, the first of its kind in Australia, to accelerate the speed and accuracy of preclinical drug development.

Phase I Clinical Trial

New Human Immune Models set to accelerate preclinical drug development

TRI-based Professor Kristen Radford from Mater Research is leading development of new preclinical research models that are core to TRI’s new Human Immune Model Facility, the first of its kind in Australia, to accelerate the speed and accuracy of preclinical drug development.

Phase I Clinical Trial

Innovative approach to Rheumatoid Arthritis

TRI-based researchers from The University of Queensland’s Frazer Institute are reprogramming the immune system to address the root cause of rheumatoid arthritis, with Phase I clinical trials showing promising results.

Phase I Clinical Trial

Innovative approach to Rheumatoid Arthritis

TRI-based researchers from The University of Queensland’s Frazer Institute are reprogramming the immune system to address the root cause of rheumatoid arthritis, with Phase I clinical trials showing promising results.

Cancer

A new era in cancer diagnosis and treatment

A team of TRI-based researchers is developing theranostic agents that combine diagnostic imaging with targeted therapy to treat difficult cancers such as ovarian, pancreatic and bladder cancer by targeting specific proteins enriched on cancer cells, enabling precise detection and treatment, and minimising damage to healthy tissues.

Cancer

A new era in cancer diagnosis and treatment

A team of TRI-based researchers is developing theranostic agents that combine diagnostic imaging with targeted therapy to treat difficult cancers such as ovarian, pancreatic and bladder cancer by targeting specific proteins enriched on cancer cells, enabling precise detection and treatment, and minimising damage to healthy tissues.

Case studies

Read about the important discoveries and breakthroughs at the forefront of translational research.

Filter by
Gut and lung focus to immune response research

Professor Gabrielle Belz leads research in understanding how the linings of the gut and lungs form a barrier, protecting the body by triggering immune responses or repairing damage.

EpilepsyNeuroscience
Studying childhood experiences in treatment-resistant epilepsy

A team of researchers and clinicians are exploring the link between early life stressors and epilepsy, paving the way for more effective treatments in the future.

GenomicsIndigenous health
Community collaboration for blood subtype study

QUT researchers are collaborating with Aboriginal and Torres Strait Islander communities to prevent complications from blood transfusions.

Indigenous health
The first 1000 days

A first study of its kind with First Nations parents aims to understand health trajectories and ensure culturally responsive healthcare is available.

Indigenous health
Partnering with indigenous communities for health and wellbeing

Research projects aim to improve health and wellbeing in areas such as cardiovascular disease, diabetes, drug and alcohol use, child health, mental health and smoking.

Breast Cancer
Better imaging for breast cancer diagnosis and treatment

TRI-based researchers from QUT are refining portable imaging technology to create 3D images of breast tissue, with the aim of improving cancer diagnosis and treatment.

Cancer
A new era in cancer diagnosis and treatment

Researchers are using theranostics to detect and treat some of the deadliest cancers, including pancreatic, ovarian, and bladder cancer.

Immunology
New Human Immune Models set to accelerate preclinical drug development

TRI-based scientists from Mater Research are developing research models that more accurately replicate the human immune system.

Prostate Cancer
Advancing prostate cancer diagnostics

Critical insights into prostate cancer have been uncovered, with researchers using them to identify therapeutic targets and developing a diagnostic tool.

Diabetes
Immunotherapy hope for children with Type 1 diabetes

Researchers are developing a new immunotherapy for people with type 1 diabetes, using the body’s own immune system to treat the disease.

Clinical ResearchRheumatoid Arthritis
Innovative approach to Rheumatoid Arthritis

A new approach to rheumatoid arthritis is being developed, with Phase I clinical trials showing promising results.

Skin cancer
Transforming skin cancer diagnosis in Australia

Research and the latest technologies are being used to change how Australia screens and diagnoses people for skin cancer.

Translational Research

Learn more about the work that happens at TRI

With over 1000 researchers and more than 20 industry organisations based at TRI, there are many important breakthroughs and developments that happen here in the field of translational research every day.

Stay abreast of what is happening via our dedicated Resources section that will keep you up-to-date on all things discovery science, clinical trials, and translational outcomes.

Translational Research

Learn more about the work that happens at TRI

With over 1000 researchers and more than 20 industry organisations based at TRI, there are many important breakthroughs and developments that happen here in the field of translational research every day.

Stay abreast of what is happening via our dedicated Resources section that will keep you up-to-date on all things discovery science, clinical trials, and translational outcomes.

Stay informed on the latest medical research with TRI's newsletter.